Outcome measures
| Outcome measures (n=140) | |
| Up-titration achieved (target dose 97/103 mg bd) | 77 (55%) |
| Reduction in loop diuretic dosage | 30 (27%) |
| SV intolerability and stopped | 11 (8%) |
| MRA dose reduced due to hyperkalaemia | 2 (2%) |
| MRA dose stopped due to hyperkalaemia | 1 (1%) |
| Postural hypotension with drop of systolic blood pressure at (>10 mmHg) | 44 (31%) |
| Hyperkalaemia (>6.0 mmol/L) | 4* (3%) |
| Deterioration in eGFR>10 | 15 (10%) |
NYHA class improvement (by 1 class) | 43 (31%) |
| Improvement in LVEF | 23† out of total 34 patients (66%) |
| Mean EF (pre-SV) (±SD) | 23% (±8.6) |
| Mean EF (post-SV) (±SD) | 30% (±10.5) |
| Mortality (6 months n=140) | 5‡ (4%) |
| Mortality (1 year n=68) | 5 (7%) |
| HF admission (6 months n=140) | 8 (6%) |
| HF admission (1 year n=68) | 4 (6%) |
*2 patients admitted to hospital.
†7 patients from LVEF <35% to >55%.
‡2 HF-related deaths, 3 non-HF-related deaths.
EF = ejection fraction; eGFR = estimated glomerular filtration rate; HF = heart failure; LVEF = left ventricular ejection fraction; MRA = mineralocorticoid receptor antagonist; NHYA = New York Heart Association; SD = standard deviation; SV = sacubitril/valsartan.